The immunocytokines market is estimated to be worth around USD 5.4 billion by 2030, claims Roots Analysis
Roots Analysis has announced the addition of the “Immunocytokines Market, 2021-2030” report to its list of offerings.

Report Keywords- Immunocytokines,ImmunocytokinesMarket, Roots Analysis,Report Analysis


Advances in molecular biology and tumor immunology have enabledthe development of therapeutic fusion proteins, having the ability to activateimmunologically cold microenvironments without the safety concerns associatedwith cytokine therapies




Roots Analysis has announced the addition of the “ImmunocytokinesMarket, 2021-2030” report to its list of offerings.


These engineeredpharmacologically-active molecules have, so far, demonstrated better efficacyand reduced toxicity compared to conventional cytokine-based therapies. As aresult, immunocytokines are now being investigated for the treatment of a widearray of target indications, including cancers, autoimmune disorders, andcertain chronic inflammatory diseases.


To order this 175+ pagereport, please visit -  


KeyMarket Insights


Over 75 immunocytokines are presently under development

Of these, 68% are designed for administrationthrough intravenous route, while 14% are designed for intratumoraladministration. Majority (50%) of the immunocytokine development programs useinterleukins as the cytokine part.


More than 85% of the firms developing immunocytokines aresmall and mid-sized initiatives

This is followed byvery large and large players, which capture nearly 15% of the overall share;examples include (in alphabetical order, no selection criteria) EMDSerono, Merck KGaA, and Roche.


Partnership activity withinthis domain has grown at a CAGR of 63%, between 2016 and 2020

Majority of the deals inked in the given time period were licensingagreements (29%), followed by mergers and acquisitions (22%).


Over 90 registered clinical trials (till November 2020)involved the evaluation of immunocytokines

Of these, 55 trials were sponsored by industry players,focused on the evaluation of immunocytokines for the treatment of various typesof cancer.


The market is anticipated to grow at a CAGR of over 40%,during the period 2024-2030

Growth in this domain is anticipated to be primarily drivenby encouraging clinical trial results and the need to reduce healthcare costsassociated with cancer. North America (primarily the US) and Europe areexpected to capture about 89% of the market share by 2030, in terms of thesales-based revenues.


To request a sample copy / brochure of this report, please visit       


Key Questions Answered

§ Who are the key playersengaged in the development of immunocytokines?

§  Which cancer indications can be treated withimmunocytokines?

§  What kind of partnership models are commonly adopted bystakeholders in this industry?

§  What are the investment trends in this industry?

§  Which are the most active clinical trial centers?

§  Who are the key opinion leaders that can help you driveyour development efforts?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?



The USD 5.4 billion (by 2030) financial opportunitywithin the immunocytokines market has been analyzed across the followingsegments:

§ Target DiseaseIndications

§ Cervical Cancer

§ Cholangiocarcinoma

§ Esophageal Cancer

§ Gallbladder Cancer

§ Head and Neck Cancer

§ Melanoma

§ Non-Small Cell LungCancer

§ Rheumatoid Arthritis

§ Soft Tissue Sarcoma


§ Routes ofAdministration

§ Intravenous

§ Intratumoral

§ Subcutaneous


§ Key geographicalregions

§ North America (US andCanada)

§ Europe (Germany, UK,France, Italy, and Spain)

§ Asia-Pacific (China,Japan, South Korea, and Australia)

§ Latin America (Braziland Argentina)

§ Middle East and NorthAfrica (Israel and Egypt)


The report featuresinputs from eminent industry stakeholders, according to whom immunocytokineswill be a multi-billion-dollar market in the future, primarily driven bypositive clinical trial outcomes. The report includes detailed transcripts ofdiscussions held with the following experts:

§ Stephen Gillies (Presidentand Chief Executive Officer, ProvenanceBiopharmaceuticals)

§ Patrik Kehler (SeniorDirector Scientific and Business Development, Glycotope)


The report covers detailed profiles of key players (listedbelow), featuring an overview of the company, its financial information (ifavailable), and a description of its product(s), highlighting type of therapyand current development status. Each profile also includes a list of recentdevelopments, and an informed opinion on the likely strategies that may beadopted by these players to fuel growth in the foreseen future.

§ Philogen

§ Merck KGaA

§ ImmunGene

§ Kanaph Therapeutics

§ Genopharm


You may also beinterested in the following titles:

1.    AntisenseOligonucleotide Therapeutics Market,2020-2030

2.     mRNATherapeutics and Vaccines Market, 2020-2030

3.     GlobalT-CellTherapies Market (5th Edition), 2021-2030


About Roots Analysis

Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at [email protected]


Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

LinkedIn -

Twitter -



You may also like

Facebook Conversations

Disqus Conversations